Form 8-K - Current report:
SEC Accession No. 0001828185-25-000018
Filing Date
2025-03-20
Accepted
2025-03-20 07:47:26
Documents
16
Period of Report
2025-03-20
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K brns-20250320.htm   iXBRL 8-K 27901
2 EX-99.1 brns-20241231xexx991.htm EX-99.1 152085
7 a1a.jpg GRAPHIC 5260
  Complete submission text file 0001828185-25-000018.txt   381035

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT brns-20250320.xsd EX-101.SCH 2640
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT brns-20250320_def.xml EX-101.DEF 16922
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT brns-20250320_lab.xml EX-101.LAB 29996
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT brns-20250320_pre.xml EX-101.PRE 17774
19 EXTRACTED XBRL INSTANCE DOCUMENT brns-20250320_htm.xml XML 4246
Mailing Address UNIT 6-10, ZEUS BUILDING RUTHERFORD AVENUE, HARWELL DIDCOT X0 OX11 0DF
Business Address UNIT 6-10, ZEUS BUILDING RUTHERFORD AVENUE, HARWELL DIDCOT X0 OX11 0DF 44 (0) 1865 818808
Barinthus Biotherapeutics plc. (Filer) CIK: 0001828185 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40367 | Film No.: 25754533
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)